Cost effectiveness of mosunetuzumab and CAR-T cell therapy in relapsed/refractory follicular lymphoma
Year: 2025
Type: article
Abstract: T cell redirecting therapies, including mosunetuzumab (mosun), axicabtagene ciloleucel (axi-cel), and tisagenlecleucel (tisa-cel), are FDA-approved for relapsed refractory follicular lymphoma (FL) in the 3rd line and beyond. There's no head-to-head clinical trial data to compare their effectiveness. These products differ in administration, hospitalization requirements, and toxicity profiles, impacting therapy selection. We developed a Markov model spanning one to 10 years from a US payer perspective, using parameters from clinical trials, quality utilities, and billing costs. Our base case analysis over 10 years showed that mosun provided $67,654 more Net Monetary Benefit (NMB) per patient than axi-cel and $111,709 more than tisa-cel. These findings suggest mosun is cost-effective at a $150,000 willingness-to-pay per QALY.
Authors: Meng-Hsuan Lin, Jonathan Weiss, Tycel J. Phillips, Dahlia Sano, Shannon A. Carty, Ryan Wilcox, Monalisa Ghosh, Iman Ahmed, Victoria R. Nachar, David Hutton, Yasmin H. Karimi
Language: English
Subfield: Economics and Econometrics
Domain: Social Sciences
Open Access status: hybrid
OpenAlex ID: W4411151237